Paper Infomation
Novel Coronavirus Disease 2019 (COVID-19) Pandemic: Research Progress of Current Medical Therapy
Full Text(PDF, 35KB)
Author: Hongji Li
Abstract: The novel coronavirus outbreak in Wuhan, Hubei Province, China in late December 2019 which poses a serious threat to the whole world. At present, the number of cases of infection is still rising. Most patients have symptoms of fever, cough and diarrhea in the early stage of the disease, and they are mainly diagnosed with pneumonia in the later stage. This disease develops rapidly, so it is very important to use drugs reasonably and treat it in the early stage. Preliminary reports indicate that certain drugs, such as chloroquine and antiviral nucleotide analogues, such as remdesivir and lopinavir/ritonavir, which inhibits viral replication, can target new coronavirus and many also used traditional Chinese medicine and other secondary therapy, although their clinical use is still under debate. Besides, scientists all over the world are racing to produce an effective vaccine for the coronavirus. This paper reviews current medical treatment strategies, and aims to provide references for new drug development and clinical workers.
Keywords: Novel Coronavirus, Clinical Trial, Drug Therapy, Potential Drug Development
References:
[1] ZHU N, ZHANG D, WANG W, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8):727- 33.
[2] World Health Organization. Coronavirus disease 2019 (COVID-19) situation report-104. https://www.who.int/docs/default-source/coronaviruse/situation-reports/ 20200503-covid-19-sitrep-104.pdf?sfvrsn=53328f46_2, Accessed date: 3 May 2020.
[3] World Health Organization（WHO）. Coronavirus disease （COVID-19） outbreak[EB/OL]． (2020-02-17)/(2020-07-03)．https：//www.who.int/
[4] CORONAVIRIDAE STUDY GROUP OF THE INTERNATIONAL COMMITTEE ON TAXONOMY OF VIRUSES (ICTV). Naming the 2019 Coronavirus[EB/OL].(2020-02-05). https://talk.ictvonline.org/information/w/news/1300/page
[5] Real-time Data Report on the Novel Coronavirus Pneumonia Epidemic[EB/OL].(2020-08-14). https://voice.baidu.com/act/newpneumonia/newpneumonia/?from=osari_aladin_banner
[6] Siyi Xin,Xueqi Cheng,Bo Zhu,Xiaolong Liao,Feng Yang,Lina Song,Yan Shi, et al. Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment[J]. Biomedicine & Pharmacotherapy, 2020, 129.
[7] Cho A, Saunders OL, Butler T, et al. Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7, 9-dideazaadenosine C-nucleosides[J]. Bioorg Med Chem Lett, 2012, 22(8): 2705-2707. DOI: 10.1016/j.bmcl.2012.02.105.
[8] Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotie coronaviruses[J]. Sci Transl Med, 2017, 9（396）：36-53
[9] Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys[J]. Nature, 2016, 531(7594): 381-385. DOI: 10.1038/nature17180.
[10] Runfeng L, Nanshan Z, Zifeng Y et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2), Pharmacological Research (2020), doi: https://doi.org/10.1016/j.phrs.2020.10476
[11] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019- nCoV) in vitro[J]. Cell Res, 2020, 30(3): 269-271. DOI: 10.1038/ s41422-020-0282-0
[12] Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States[J]. N Engl J Med, 2020, 382(10): 929-936. DOI: 10.1056/NEJMoa2001191.
[13] Yeming Wang, Dingyu Zhang, Bin Cao, Chen Wang, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial[J]. TheLancet, https://doi.org/10.1016/S0140-6736(20)31022-9
[14] J.H. Beigel, K.M. Tomashek, L.E. Dodd, A.K. Mehta, et al. Remdesivir for the Treatment of Covid-19—PreliminaryReport[J].The New England journal of medicine DOI : 10. 1056/ NEJ Moa2007764
[15] Gilead Announces Results From Phase 3 Trial of Investigation Antiviral Remdesivir in Patients With Severe COVID-19[EB/OL]. https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/
[16] Van Vugt M, White NJ. The treatment of chloroquine-resistant malaria [J]. Trop Doct, 1999, 29: 176-179.
[17] Plantone D, Koudriavtseva T. Current and future use of chloro‐ quine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review [J]. Clin Drug Invest, 2018, 38: 653-671.
[18] Adrea Savarino, John R Boelaert, Antonio Cassone, Giancario Majori, Roberto Cauda. Effects of chloroquine on viral infections: an old drug against today’s diseases[J] . The Lancet Infectious Diseases. 2003 (11)
[19] MohsinKhan, S.R. Santhosh, Mugdha Tiwari, P.V. LakshmanaRao, ManmohanParida. Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against chikungunya virus in vero cells[J] . Med. Virol. 2010 (5)
[20] National Health Commission of the People's Republic of China: Notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 7) [EB/OL]. Medical administration and hospital authority, 2020 [2020-03-04]. http://www.nhc.gov.cn/yzygj/s7653p/202003/ 46c9294a7dfe4cef80dc7f5912eb1989.shtml
[21] Joshua Geleris, M.D., Yifei Sun, Ph.D., Jonathan Platt, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19[J]. The New England journal of medicine, DOI: 10.1056/NEJMoa2012410
[22] Tang W, Cao Z , Han M , et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial[J]. BMJ (online), 2020, 369:m1849.
[23] Hoffmann, M., Mösbauer, K., Hofmann-Winkler, H. et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature (2020). https://doi.org/10.1038/s41586-020-2575-3
[24] National Health Commission, Office of the State Administration of Traditional Chinese Medicine. New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 7) [EB/OL].(2020-03-04)/(2020-07-16).http://www.nhc.gov.cn/yzygjhttp://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[25] Zhu Shunya, Li Xiaoyu, Wei Yunling, et al. Preliminary study on the in vitro inhibitory effects of three traditional Chinese medicine prescriptions on SARS-related coronavirus[J].Biotechnology Communications,2003(5):390-392.
[26] Ding Xinkan. Pharmacological analysis of Lianhua Qingwen drug against influenza virus[J].Journal of Clinical Rational Use of Medicines,2012,5(28):32
[27] Niu Ming, Wang Ruilin, Wang Zhongxia, et al. The rapid selection mode and application of anti-new coronavirus TCM prescriptions based on clinical experience and molecular docking technology [J/OL]. Chinese Journal of Chinese Materia Medica: 1-8
[28] Runfeng L, Nanshan Z, Zifeng Y et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2), Pharmacological Research (2020), doi: https://doi.org/10.1016/j.phrs.2020.10476
[29] Ke Hu, Wei-jie Guan, Ying Bi, Zhen-hua Jia, Nan-shan Zhong, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial[J]. Phytomedicine, 2020.
[30] Croxtall JD, Perry CM. Lopinavir/ritonavir [J]. Drugs, 2010, 70: 1885-1915
[31] Chu MC. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings [J]. Thorax, 2004, 59: 252-256
[32] Nukoolkarn V, Lee VS, Malaisree M, et al. Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors [J]. J Theor Biol, 2008, 254: 861-867.
[33] Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects [J]. PLoS Med, 2006, 3: e343
[34] Chen J, Ling Y, Xi XH, et al. Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia [J]. Infect Disease of China, 2020, 38: 86-89.
[35] B. Cao, Y. Wang, D. Wen, W. Liu, Jingli Wang, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19[J]. The New England journal of medicine, DOI :10.1056 / NEJMoa2001282
[36] WANG K, CHEN W, ZHOU Y, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spikeprotein[EB/OL].(2020-03-10)/(2020-07-22).https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1.full.pdf.
[37] Shiva Shaghaghi,Mahyar Daskareh,Mona Irannejad,Mohammadreza Shaghaghi,Ihab R. Kamel. Target-shaped combined halo and reversed-halo sign, an atypical chest CT finding in COVID-19[J]. Clinical Imaging, 2021, 69.
[38] TIAN Xiaolong, LI Cheng, HUANG Ailing, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody[J]. Emerg Microbes Infect, 9 (1): 382-385.
[39] CHEN J, ZHU H, HORBY P W, et al. Specificity, kinetics and longevity of antibody responses to avian influenza A(H7N9) virus infection in humans[J]. J Infect, 2020, 80(3):310-319.
[40] ARABI Y M, HAJEER A H, LUKE T, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia[J]. Emerg Infect Dis, 2016, 22(9):1554-61.
[41] K. Duan, B. Liu, C. Li, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc. Natl. Acad. Sci. U.S.A. 117 (2020) 9490–9496
[42] M. Ye, D. Fu, Y. Ren, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China, J. Med. Virol. (2020)
[43] Hassan Abolghasemia, Peyman Eshghib, Abdol Majid Cheraghali, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study[J]. Transfusion and Apheresis Science (in press)